Amgen Inc BDR (AMGN34)

49.65 -0.07 (-0.14%)
Close BRL Disclaimer

Amgen Inc BDR Company Profile

Industry
Pharmaceuticals
Sector
Healthcare
Employees
25200
Equity Type
DRC
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Contact Information
Address
Thousand Oaks,91320-1799 United States
Phone
805 447 1000
Fax
805 447 1010
Top Executives
Name
Age
Since
Title
Robert A. Bradway 58 2007 Chairman, CEO & President
Robert A. Eckert 69 2012 Lead Independent Director
Greg C. Garland 66 2013 Independent Director
Tyler E. Jacks 62 2012 Independent Director
Brian J. Druker 68 2018 Independent Director
Ellen J. Kullman 67 2016 Independent Director
David Baltimore 85 1999 Co-Chair of Scientific Advisory Board
Wanda M. Austin 69 2017 Independent Director
Amy E. Miles 56 2020 Independent Director
S. Omar Ishrak 67 2021 Independent Director
Diane J. Mathis 0 0000 Member of Scientific Advisory Board of Inflammation
Ronald D. Sugar 74 2010 Independent Director
R. Sanders Williams 74 2014 Independent Director
Alexander Marson 0 2022 Member of Scientific Advisory Board of Inflammation
Arlene Sharpe 0 2022 Member of Scientific Advisory Board of Inflammation
Charles M. Holley 66 2017 Independent Director
Lillian L. Siu 0 2022 Member of Scientific Advisory Board of Oncology
S. Gail Eckhardt 0 2022 Member of Scientific Advisory Board of Oncology
Richard O. Hynes 0 0000 Member of Scientific Advisory Board of Research Trends & Emerging Technologies
Maria T. Abreu 0 2022 Member of Scientific Advisory Board of Inflammation
Michael V. Drake 72 2022 Independent Director
Emma Guttman-Yassky 0 2022 Member of Scientific Advisory Board of Inflammation
Meilan Han 0 2022 Member of Scientific Advisory Board of Inflammation
Dirk Jäger 0 0000 Member of Scientific Advisory Board of Oncology
Robert S. Negrin 0 0000 Member of Scientific Advisory Board of Oncology
Daniel P. Kelly 0 0000 Member of Scientific Advisory Board of Cardiovascular & Metabolic
Robert Tjian 74 0000 Member of Scientific Advisory Board Member of Research Trends & Emerging Technologies
Siwen Hu-Lieskovan 0 0000 Member of Scientific Advisory Board of Oncology
Frank P. McCormick 73 0000 Member of Scientific Advisory Board of Research Trends & Emerging Technologies
Ronald M. Evans 74 0000 Member of Scientific Advisory Board of Research Trends & Emerging Technologies
John Kuriyan 0 0000 Member of Scientific Advisory Board of Research Trends & Emerging Technologies
Jeffery D. Molkentin 0 0000 Member of Scientific Advisory Board of Cardiovascular & Metabolic
George Georgiou 64 2023 Member of Scientific Advisory Board of Research Trends & Emerging Technologies
David Alan Kass 0 0000 Member of Scientific Advisory Board of Cardiovascular & Metabolic
E. Dale Abel 0 0000 Member of Scientific Advisory Board of Cardiovascular & Metabolic
Elizabeth McNally 0 0000 Member of Scientific Advisory Board of Cardiovascular & Metabolic
Jonathan S. Weissman 0 0000 Member of Scientific Advisory Board of Research Trends & Emerging Technologies
Drew Mark Pardoll 0 0000 Member of Scientific Advisory Board of Oncology
Marlene Rabinovitch 0 0000 Member of Scientific Advisory Board of Cardiovascular & Metabolic
Dean Sheppard 0 2022 Member of Scientific Advisory Board of Inflammation
Alexander Rudensky 0 2022 Member of Scientific Advisory Board of Inflammation
Antoni Ribas 0 0000 Member of Scientific Advisory Board of Oncology
Benoit Van den Eynde 0 0000 Member of Scientific Advisory Board of Oncology
David J. Anderson 0 0000 Member of Scientific Advisory Board of Research Trends & Emerging Technologies
Peter Libby 76 0000 Member of Scientific Advisory Board of Cardiovascular & Metabolic
Ruslan Medzhitov 0 0000 Member of Scientific Advisory Board of Research Trends & Emerging Technologies
Daniel Joshua Drucker 0 0000 Member of Scientific Advisory Board of Cardiovascular & Metabolic
Charles Elliott Sigal 72 0000 Co-Chair of the Scientific Advisory Board
Thomas Quertermous 72 0000 Member of Scientific Advisory Board of Cardiovascular & Metabolic
Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles